enthusiasm dramatically outpaces science FDA Category 2 classifications for peptides like Semax reflect absence of FDA-standard evidence, not documented harmsRussian clinical experience suggests reasonable safety, but long-term effects by Western standards remain uncharacterized Established interventionsexercise, Mediterranean diet, sleep optimization, cardiovascular risk management, cognitive engagementhave far more consistent evidence than any peptide for dementia risk reduction For Research Prioritization Compounds meriting continued investigation: GLP-1 Agonists: Prevention trials in preclinical/presymptomatic populations, testing compounds with better brain penetration (dulaglutide, lixisenatide) SS-31/Elamipretide: Cognitive outcomes in mitochondrial disease populations, potential expansion to brain aging indications P21: Phase I human trials to establish safety, pharmacokinetics, and proof-of-mechanism for CNTF-pathway neurogenesis Klotho: Watch for Phase 1 results from Jocasta Neuroscience (expected 2027-2028)
Following the trial, the femur samples underwent additional analysis with mid-diaphyseal peripheral quantitative computed tomography (pQCT) scans
BPC-157 10mg is supplied strictly as a research chemical for in-vitro laboratory use
Pain and Inflammation Relief : Targeting joint pain and reducing systemic inflammation
Immune & Cellular Health: Complete Blood Count Iron & Total Iron-binding Capacity Vitamin D RBC Magnesium Ferritin Hormones & Blood Sugar: Hemoglobin A1c Thyroid-Stimulating Hormone Inflammation: C-Reactive Protein Homocysteine Body Systems: Comprehensive Metabolic Panel Add-Ons: Blood Typing Nutritional Assessment Testing Omega 3 & 6 Fatty Acids NMR Lipoprofile with Insulin Resistance Markers Food Sensitivity Panel Complete Thyroid Panel Individual markers are available Book Now Protocol Panels $499 Our unique Protocol Panels take a deeper look at key wellness areas including performance, metabolic function, recovery, skin wellness, and overall vitality
